CASI Pharmaceuticals (NASDAQ:CASI) announces the product launch of EVOMELA (melphalan for injection) in China.
EVOMELA was approved for the use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
It is the only approved and commercially available melphalan product in China.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.